Idiopathic pulmonary arterial hypertension in children

被引:25
作者
Rosenzweig, EB [1 ]
Barst, RJ [1 ]
机构
[1] Columbia Univ, Med Ctr, Pulm Hypertens Ctr, Dept Pediat, New York, NY 10032 USA
关键词
children; epoprostenol; idiopathic pulmonary arterial hypertension;
D O I
10.1097/01.mop.0000163356.51027.c1
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Purpose of review Until recently, the diagnosis of idiopathic pulmonary arterial hypertension was virtually a death sentence, particularly for children. Although there is no cure for idiopathic pulmonary arterial hypertension, recent medical advances have dramatically changed the course of this disease in children. A review of some of the latest medical advances will provide the reader with a better understanding of the most current treatment options for children with idiopathic pulmonary arterial hypertension. Recent findings The literature reviewed demonstrate sustained clinical and hemodynamic improvement in children with various types of pulmonary arterial hypertension as well as increased survival in patients with idiopathic pulmonary arterial hypertension using current treatment strategies. Summary This article will provide an overview of how the current diagnostic and treatment strategies of idiopathic pulmonary arterial hypertension in children have advanced over the last several years and how this impacts on clinical practice.
引用
收藏
页码:372 / 380
页数:9
相关论文
共 66 条
[1]  
Abrams D, 2000, Heart, V84, pE4, DOI 10.1136/heart.84.2.e4
[2]  
Barst RJ, 2000, EUR HEART J, V21, P315
[3]   Sitaxsentan therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
Langleben, D ;
Frost, A ;
Horn, EM ;
Oudiz, R ;
Shapiro, S ;
McLaughlin, V ;
Hill, N ;
Tapson, VF ;
Robbins, IM ;
Zwicke, D ;
Duncan, B ;
Dixon, RAF ;
Frumkin, LR .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2004, 169 (04) :441-447
[4]   Vasodilator therapy for primary pulmonary hypertension in children [J].
Barst, RJ ;
Maislin, G ;
Fishman, AP .
CIRCULATION, 1999, 99 (09) :1197-1208
[5]   Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension - Open-label pilot study [J].
Barst, RJ ;
Rich, S ;
Widlitz, A ;
Horn, EM ;
McLaughlin, V ;
McFarlin, J .
CHEST, 2002, 121 (06) :1860-1868
[6]   A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].
Barst, RJ ;
Rubin, LJ ;
Long, WA ;
McGoon, MD ;
Rich, S ;
Badesch, DB ;
Groves, BM ;
Tapson, VF ;
Bourge, RC ;
Brundage, BH ;
Koerner, SK ;
Langleben, D ;
Keller, CA ;
Murali, S ;
Uretsky, BF ;
Clayton, LM ;
Jobsis, MM ;
Blackburn, SD ;
Shortino, D ;
Crow, JW .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301
[7]   Beraprost therapy for pulmonary arterial hypertension [J].
Barst, RJ ;
McGoon, M ;
McLaughlin, V ;
Tapson, V ;
Oudiz, R ;
Shapiro, S ;
Robbins, IM ;
Channick, R ;
Badesch, D ;
Rayburn, BK ;
Flinchbaugh, R ;
Sigman, J ;
Arneson, C ;
Jeffs, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (12) :2119-2125
[8]  
Barst RJ, 2000, CIRCULATION, V102, P100
[9]   SURVIVAL IN PRIMARY PULMONARY-HYPERTENSION WITH LONG-TERM CONTINUOUS INTRAVENOUS PROSTACYCLIN [J].
BARST, RJ ;
RUBIN, LJ ;
MCGOON, MD ;
CALDWELL, EJ ;
LONG, WA ;
LEVY, PS .
ANNALS OF INTERNAL MEDICINE, 1994, 121 (06) :409-415
[10]  
BARST RJ, 2003, CLIN PHARMACOL THER, V73, P87